Clinical and Biological Relevance of Statin-Mediated Changes in HDL Metabolism

Statin Drugs (MB Clearfield, Section Editor)

DOI: 10.1007/s11883-013-0379-8

Cite this article as:
Arsenault, B.J. & Boekholdt, S.M. Curr Atheroscler Rep (2014) 16: 379. doi:10.1007/s11883-013-0379-8
Part of the following topical collections:
  1. Topical Collection on Statin Drugs


Although prospective studies consistently show that individuals with low levels of high-density lipoprotein (HDL) cholesterol are at increased cardiovascular risk, it is still not clear whether or not this relationship still holds in patients treated with statins who have achieved optimal low-density lipoprotein cholesterol levels. Additionally, the hypothesis that statin-mediated increases in HDL cholesterol levels have a impact on cardiovascular risk has not been clearly demonstrated. Statin therapy has little impact on the cholesterol content carried by HDL in the bloodstream (i.e., HDL cholesterol levels), but statins can induce a significant redistribution of HDL particle size, particle concentration, and physicochemical and functional properties. Our objective is to summarize the evidence arising from epidemiological, clinical, and experimental studies that suggests a potential role for statin therapy in the modulation of parameters of HDL metabolism and reverse cholesterol transport.


High-density lipoproteins High-density lipoprotein functionality Cholesterol efflux capacities Cholesteryl ester transfer protein Statins Cardiovascular disease 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de QuebecQuebecCanada
  2. 2.Department of Medicine, Faculty of MedicineUniversité LavalQuebecCanada
  3. 3.Department of CardiologyAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations